Navigation Links
Chemoembolization Improving as Liver Cancer Treatment
Date:1/19/2009

kage of blood that could feed the tumor.

More than 21,000 people are diagnosed with liver and bile duct cancer, and more than 18,000 will die of the disease each year, according to the American Cancer Society.

Hope for People with Liver Cancer

A study at St. Joseph's Hospital and Medical Center in Tampa, Fla., included 25 patients who had colorectal cancer that had spread to the liver and 11 with primary liver cancer. All of the patients with primary liver cancer received LC Beads(TM) that emitted doxorubicin, a type of chemotherapeutic agent, while 13 of the colorectal patients received doxorubicin-emitting beads and 12 received beads that emitted irinotecan, another chemotherapeutic agent. The patients who received the doxorubicin-eluting beads fared better - 10 of 11 (91 percent) of the primary liver cancer patients and 10 of the 13 (77 percent) of the colorectal patients were alive after two years. Conversely, one of 12 (8.3 percent) of the irinotecan patients were alive after two years. Researchers are studying why doxorubicin appears to work better in these cases.

LC Beads slowly elute the chemotherapuetic agent over the course of two weeks, providing a constant dose of the drug to the tumor, without leading to systemic side effects.

"There is definitely a chance of cancer cure with this procedure beyond just palliation," said Glenn Stambo, M.D., vascular and interventional radiologist at St. Joseph's Hospital and Medical Center. "The more isolated the tumor and its blood vessel feeders, the better the chance for a complete cure."

Improvements in Chemoembolization

A multicenter Italian trial used HepaSphere(TM) beads loaded with chemotherapeutic agents to deliver treatment to 53 patients with liver cancer. HepaSpheres are designed to expand after they lodge in the arteries that feed the tumor, so that blood flow is more effectively blocked;
'/>"/>

SOURCE International Symposium on Endovascular Therapy
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Stroke Study Reveals a Key Target For Improving Treatment
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
9. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Wis., Dec. 16 Cellular ... commercial launch of iCell(TM) Cardiomyocytes for use in ... industry. These human heart cells are designed ... of drug compound efficacy and toxicity screens, weeding ... the pharmaceutical pipeline process before significant time and ...
(Date:12/15/2009)... INCLINE VILLAGE, Nev., Dec. 15 PDL BioPharma, ... it has paid the December 15, 2009 special dividend ... shares of PDL as of December 1, 2009. ... ended December 31, 2009 total $2.67 per share. ... regarding the federal tax characteristics of the Company,s 2009 ...
(Date:12/15/2009)... 15 The U.S. Food and Drug Administration ... voted 12 yes, 4 no, and 1 abstention that ... risks to support the use of CRESTOR® (rosuvastatin calcium) ... greater than or equal to 50 years, women greater ... LDL < 130 mg/dL; hsCRP greater than or equal ...
Breaking Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4PDL BioPharma Completes December 15 Special Dividend Payment 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 1Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 2The Sensory Research Center 28SRC 29 Offers 2 for 1 Tickets for Benefit Concert Supporting Autism Downs Syndrome Cerebral Palsy and Other Disabilit 55001 1The Sensory Research Center 28SRC 29 Offers 2 for 1 Tickets for Benefit Concert Supporting Autism Downs Syndrome Cerebral Palsy and Other Disabilit 55001 2Study finds low risk in treating previously coiled aneurysm 54998 1Study finds low risk in treating previously coiled aneurysm 54998 2Study finds low risk in treating previously coiled aneurysm 54998 3
(Date:12/15/2009)... a Life Sciences company engaged in the research, development and commercialization of technologies that target ... the Company had proposed at the Annual General Meeting of Shareholders held on December 14, ... Votes ... Non-, Matter ... For Against ...
(Date:12/15/2009)... Lourdes Health Care Services Inc., the parent company of ... United States $7.95 million to resolve allegations that the ... two hospitals are Our Lady of Lourdes Medical Center ... Burlington County (LMC) in Willingboro, N.J. ,, LMC ... whistleblower, Tony Kite, in 2005. The lawsuit alleged that ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
(Date:12/15/2009)... 4R Systems, Inc., a leading provider ... help retailers significantly increase profits by optimizing their ... that The Vitamin Shoppe has been utilizing the ... and DC inventory solutions have helped us drive ... over the last two years," said Tony Truesdale, ...
(Date:12/15/2009)... -- North American application activity for individually underwritten ... to the MIB Life Index(SM) . ... past three months have lifted year-to-date (YTD) figures ... flat at November,s close, -0.1%. "It is ... benefits available from life insurance," says Stacy Gill, ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... Swartz Center for Computational Neuroscience at UC San Diego ... body/brain dynamics of subjects engaged in normal activity in ... under a four year, $3.4 million research grant from ... developing a concurrent brain and body imaging modality MoBI ...
... Healthcare Management Systems,Inc.(R) (HMS) hospital customers completed three ... painted were entered into a drawing,to receive the paintings ... another,hospital. Recipients of the 4-foot by 6-foot, multiple-canvas paintings ... of HMS, annual,conference. , , ...
... Md., Dec. 10 Approximately 38 percent of adults in ... 12 percent of U.S. children aged 17 years and under ... to a new nationwide government survey (1). ... on children,s use of CAM, which is a group of ...
... Epiretinal Brachytherapy Granted Compassionate Use to Attempt to Prevent ... , FREMONT, Calif., Dec. 10 ... Drug Administration (FDA) had approved the company,s "compassionate case" ... (AMD) treatment on a patient with an advanced form ...
... neurodegenerative diseases , , WEDNESDAY, Dec. 10 (HealthDay News) -- ... death of neurons in the brains of patients with ... U.S. researchers. , The finding could help in the ... , The scientists focused on an enzyme called HDAC1, ...
... As do 12% of children, new government survey says ... estimated 38 percent of U.S. adults and 12 percent ... medicine, a new U.S. government survey finds. , Complementary ... an umbrella term for a collection of wide-ranging medical ...
Other Medicine News:Health News:HMS Donates Hospital Art 2Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 2Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 3Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 4Health News:According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine 5Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 3Health News:38% of U.S. Adults Use Alternative Treatments 2Health News:38% of U.S. Adults Use Alternative Treatments 3
... of three software components that comprise ... ,Three software components comprise the SmartPill ... software, SmartPill Data Receiver software and ... are integrated and indispensable parts of ...
... software links sampler, patient and ... making data readily available to ... of incorrect patient identification. ... 1st automatic, the worlds first ...
... One of three software components that ... ,Three software components comprise the ... Capsule software, SmartPill Data Receiver software ... components are integrated and indispensable parts ...
... Testing Application for POLYGRAM NET® ... Catheter-Free pH Monitoring System, Digitrapper™ ... Synectics Digitrapper MkIII catheter-based pH ... and Digitrappers use Medtronic Slimline®, ...
Medicine Products: